| 4.57 0.088 (1.97%) | 08-19 12:13 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.36 |
1-year : | 7.43 |
| Resists | First : | 5.45 |
Second : | 6.36 |
| Pivot price | 0.83 |
|||
| Supports | First : | 2.36 |
Second : | 0.45 |
| MAs | MA(5) : | 1.34 |
MA(20) : | 0.76 |
| MA(100) : | 0.63 |
MA(250) : | 0.87 |
|
| MACD | MACD : | 0.3 |
Signal : | 0 |
| %K %D | K(14,3) : | 49.7 |
D(3) : | 34.5 |
| RSI | RSI(14): 96.8 |
|||
| 52-week | High : | 5.45 | Low : | 0.41 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GLMD ] has closed above the upper band by 43.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 1598.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.58 - 0.58 | 0.58 - 0.59 |
| Low: | 0.52 - 0.52 | 0.52 - 0.53 |
| Close: | 0.55 - 0.56 | 0.56 - 0.57 |
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Wed, 19 Aug 2026
A new technology measured colon tissue in all 32 patients with no failures - Stock Titan
Fri, 31 Jul 2026
Galmed Pharmaceuticals (NASDAQ: GLMD) granted new deadline to meet $1 bid rule - Stock Titan
Fri, 24 Jul 2026
Galmed Pharmaceuticals Ltd. Revenue Breakdown – NASDAQ:GLMD - TradingView
Fri, 26 Jun 2026
Galmed Pharmaceuticals Ltd. Actuals & Estimates (NASDAQ:GLMD) - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 1.7 (%) |
| Shares Short | 30 (K) |
| Shares Short P.Month | 281 (K) |
| EPS | -2.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.1 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -33.5 % |
| Return on Equity (ttm) | -72.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -2.24 |
| PEG Ratio | 0 |
| Price to Book value | 2.18 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|